RAP1GAP and cervical cancer: To determine whether the down-regulation of Rap1GAP in cervical cancer cells was due to proteasome-mediated degradation, the cells were treated with a proteasome inhibitor, MG132, and the levels of Rap1GAP in the cells were analyzed before and after the treatment.